United States: FDA-Approved Labeling ≠ Medical Standard Of Care

Last Updated: February 23 2017
Article by James Beck

We've been defending the ability of physicians to engage in off-label use ever since the Bone Screw litigation of the 1990s. Buckman Co. v. Plaintiffs Legal Committee, where the United States Supreme Court affirmed that "off-label use is generally accepted" and that under the law, "[p]hysicians may prescribe drugs and devices for off-label uses," 531 U.S. 341, 351 & n.5 (2001), was one of our Bone Screw cases. Thus, we follow medical malpractice decisions, like Doctors Co. v. Plummer, ___ So.3d___, 2017 WL 242577 (Fla. App. Jan. 20, 2017), which we discussed recently, for what they have to say about off-label use. In malpractice cases, the dark side often attempts to equate "intended uses" listed in FDA-approved drug/device labeling with the medical standard of care. As we mentioned in that post, arguments that FDA-approved product labeling equals the medical standard of care are really attempts to turn off-label use itself into a tort.

The Doctors Co. decision prompted us to look back over our 9+ years of blogging output for where we addressed this issue previously. Surprisingly, there was only one, a 2007 Bexis piece that (even more surprisingly) didn't cite any caselaw. We also found a 2009 law review article by our erstwhile co-founder, Mark Herrmann, which might have been prompted by the earlier blogpost. But nothing was on the blog itself that could qualify as useful research.

We rectify that today.

As we suspected, the modern rule severely limit the use of FDA-approved labeling as evidence of any medical standard of care in medmal cases. The New Jersey Supreme Court, in Morlino v. Medical Center, 706 A.2d 721 (N.J. 1998), rejected an argument that, because the defendant physician had not disclosed a pregnancy-related risk contained in the package insert (as collected in the Physician's Desk Reference ("PDR"), that proved malpractice.

[D]rug manufacturers do not design package inserts and PDR entries to establish a standard of medical care. Manufacturers write drug package inserts and PDR warnings for many reasons including compliance with FDA requirements, advertisement, the provision of useful information to physicians, and an attempt to limit the manufacturer's liability. . . . Those considerations highlight the reasons expert testimony must accompany the introduction of PDR warnings to establish the applicable standard of care in prescribing a drug.

Id. at 729. In Dunn v. Yager, 58 So.3d 1171, 1203 (Miss. 2011), the court affirmed exclusion of an FDA black box warning in a malpractice case, where the warning had not been present at the time of the medical treatment in question.

Another attempt to measure the medical standard of care by drug labeling failed in McCorkle v. Gravois, 152 So.3d 944 (La. App. 2014). Agreeing with Morlino, the McCorkle court:

conclude[d] that in the absence of a specific contraindication or warning in the package insert and PDR, the plaintiffs could not satisfy their burden of establishing the applicable standard of care, nor establish a prima facie case of negligence, by relying upon the package insert and PDR alone, but instead, needed expert testimony.

Id. at 956. Similarly, the court in Chandler v. Simpson, 2000 WL 426441, at *8 (Wash. App. April 18, 2000), refused to allow a warning from a package insert to establish "materiality" for purposes of informed consent. Other cases rejecting evidentiary use of FDA-approved drug/device labeling in medical malpractice cases are: Anderson v. Eli Lilly & Co., 2015 WL 8773795, at *3 (Ohio App. Dec. 15, 2015) (expert testimony required; "that a physician prescribed a medication which arguably was contraindicated . . . does not in and of itself make the treating physician guilty of professional negligence"); Clarke v. Mikhail, 779 S.E.2d 150, 161 (N.C. App. 2015) (a "manufacturer's recommended titration schedule is a recommendation only, from which medical providers can and do deviate"); Arnold v. Lee, 2006 WL 1410161, at *3 (Iowa App. May 24, 2006) (refusing to admit package insert as evidence of malpractice "[i]n an age where drugs are frequently used for purposes not approved by the FDA") (in table at 720 N.W.2d 194); cf. Schultz v. AstraZeneca Pharmaceuticals, L.P., 2006 WL 3797932, at *4 (N.D. Cal. Dec. 22, 2006) ("a mere allegation of 'off-label' use with nothing more would not be sufficient to state a claim for professional negligence").

Most jurisdictions will admit package inserts in malpractice cases, but not as conclusive evidence of a violation of the standard of care, and usually only in conjunction with expert testimony. "[T]he majority view [is] that while the information about the drug in the package insert and the PDR is relevant and useful information regarding the prescribing physician's standard of care, it is not the sole determinant of the standard of care." Hyman & Armstrong, P.S.C. v. Gunderson, 279 S.W.3d 93, 114 (Ky. 2008). In Spensieri v. Lasky, 723 N.E.2d 544 (N.Y. 1999), the New York Court of Appeals, declared that "[t]he purposes behind [drug labeling] render its content ill-suited to serve as prima facie evidence of a standard of care," and consequently "reject[ed] the contention that the PDR constitutes prima facie evidence of a standard of care." "[A]dmission of the PDR alone in place of expert testimony would result in a standard of care established by drug manufacturers instead of the medical profession." Id. at 548.

In Richardson v. Miller, 44 S.W.3d 1 (Tenn. App. 2000), the court distilled (mostly from Spensieri) four reasons for restricting the use of manufacturer/FDA labeling in medical malpractice cases relating to the standard of care:

  • First, permitting the labeling or the PDR reference alone to establish a physician's standard of care would be inconsistent with [state statutory law] because it would permit the drug manufacturer, rather than the medical profession, to establish the standard of care.
  • Second, the FDA-required labeling and parallel PDR reference may not be easily understood by the jury without expert assistance because these materials are written for the medical profession, not the general public.
  • Third, the drug manufacturer and the FDA do not intend to establish the standard of care when they prepare a drug's labeling or PDR reference. These materials are intended to comply with the FDA's regulations, to provide advertising and promotional material, and to limit the manufacturer's liability.
  • Finally, the labeling and PDR reference cannot be cross-examined.

Id. at 16-17 (citations omitted).

Other cases allowing use of manufacturer labeling in a role subsidiary to expert testimony in medical malpractice/informed consent litigation against physicians include: Ngo v. Queen's Medical Center, 358 P.3d 26, 41 (Haw. 2015) ("information contained in a manufacturer's insert cannot, on its own, satisfy a plaintiff's burden of production in an informed consent case, [but] can constitute evidence that the jury or fact finder may consider along with the requisite expert testimony"); Bissett v. Renna, 710 A.2d 404, 407 (N.H. 1998) ("the PDR, by itself, is insufficient to establish the standard of care required of the defendant"); Craft v. Peebles, 893 P.2d 138 (Haw. 1995) ("manufacturer's package inserts do not, by themselves, set the standard of care which is applicable to a physician on the issue of informed consent"); Bowman v. Songer, 820 P.2d 1110, 1114 (Colo. 1991) ("manufacturer's instructions . . . may be admissible evidence on the standard of care, when supported by expert testimony"); Ramon v. Farr, 770 P.2d 131, 135-36 (Utah 1989) ("the better rule is that manufacturers' inserts and parallel P.D.R. entries do not by themselves set the standard of care, even as a prima facie matter" but are "some evidence that the finder of fact may consider along with expert testimony on the standard of care"); Garvey v. O'Donoghue, 530 A.2d 1141, 1146 (D.C. 1987) ("[w]hen the package insert or the PDR is offered in conjunction with expert testimony . . . that combination may be sufficient to establish the standard of care"); Thompson v. Carter, 518 So.2d 609, 613 (Miss. 1987) ("the package insert in the instant case should not be taken as conclusive evidence of the physician's standard of care, nor should a departure from the directions contained in the package insert be considered to establish a prima facie case of negligence"; but is admissible as proof "of the proper method of use"); Nolan v. Dillon, 276 A.2d 36, 49 (Md. 1971) ("[t]he package insert . . . does not standing alone establish a standard of care, but rather, prima facie proof of proper use"); Crouch v. Most, 432 P.2d 250, 252 (N.M. 1967) ("directions in the brochure are, at best, only proof of a proper method of use"); Doctors Co., ___ So.3d at ___, 2017 WL 242577, at *6 ("a prescription drug package insert may have some significance in identifying a doctor's standard of care" but "cannot be used as 'stand-alone proof'"); Grayson v. State, 838 P.2d 546, 548-49 (Okla. App. 1992) ("declin[ing] to hold that departure from the drug manufacturer's recommendations found on the package insert is prima facie evidence of negligence"; they may only "be considered along with all other evidence," and "do[] not relieve the plaintiff of the burden of proving, through expert testimony, the standard of medical care") (emphasis original); Gaston v. Hunter, 588 P.2d 326, 345 n.18 (Ariz. App. 1978) ("manufacturer's instructions are at least some evidence of the appropriate standard of care in the administration of a drug"); Rodriguez v. Jackson, 574 P.2d 481, 486 (Ariz. App. 1977) ("the package insert is admissible into evidence, [but] does not establish conclusive evidence of the standard or accepted practice in the use of the drug by physicians and surgeons"); Salgo v. Leland Stanford, Jr. University Board of Trustees, 317 P.2d 170, 180 (Cal. App. 1957) (package inserts "while admissible, . . . cannot establish as a matter of law the standard of care required of a physician in the use of the drug"); Bay v. Abel, 2004 WL 5453008 (Okla. Dist. April 21, 2004) ("non-approval by the FDA with regard to the [device] and technique utilized by [the physician] does not, per se, demonstrate or prove professional malpractice").

Some courts, in mostly older decisions, allow package inserts, without more, to stand as "prima facie" evidence of the medical standard of care. Mueller v. Mueller, 221 N.W.2d 39, 42-43 (S.D. 1974); Ohligschlager v. Proctor Community Hospital, 303 N.E.2d 392, 386 (Ill. 1973); Mulder v. Parke Davis & Co., 181 N.W.2d 882, 887 (Minn. 1970); Julien v. Barker, 272 P.2d 718, 724 (Idaho 1954); Haught v. Maceluch, 681 F.2d 291, 303 n.12 (5th Cir. 1982) (applying Texas law). Interestingly, this approach tended to exculpate manufacturers from liability for off-label use, while imposing such liability on physicians:

The drug manufacturers are being held accountable in courts of law for injuries caused by these drugs only when these recommendations are followed. The busy doctor has no alternative but to prescribe these drugs according to the recommendations of the drug manufacturers.

Mueller, 221 N.W.2d at 42-43 (emphasis added).

Finally, that a prescription medical product has been prescribed off-label has been held not to undermine a statutory presumption that the product's FDA approved labeling was adequate:

The decision of [plaintiff's] physicians to prescribe [the drug] off-label, and the fact that the FDA had not yet approved [it] for the particular indication for which it was prescribed to [plaintiff], does not rebut the statutory presumption of adequacy to which the [drug's] labeling is entitled. . . . The FDA's decision not to include a risk . . . warning on the [drug's] label was deliberate and informed. Plaintiffs cannot use the fact that [the drug] was prescribed off-label to rebut the statutory presumption of adequacy.

Bailey v. Wyeth, Inc., 37 A.3d 549, 576 (N.J. Super. Law. Div. 2008) (product liability action; "[f]ollowing the accepted medical standard of care, physicians frequently prescribe drugs for off-label or unapproved uses"), aff'd, 28 A.3d 1245 (N.J. Super. App. Div. 2011). Accord Seavey v. Globus Medical, Inc., 2014 WL 1876957, at *7-8 (D.N.J. March 11, 2014) (applying same statutory presumption as Bailey to off-label use of §510k medical device).

This article is presented for informational purposes only and is not intended to constitute legal advice.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

James Beck
In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.